5 Insightful Analyst Questions From Fortrea's Q2 Earnings Call

Fortrea’s second quarter results were well received by the market, with management pointing to robust performance in its clinical pharmacology segment and ongoing margin optimization initiatives. Chairman Peter Neupert credited “continued progress against the company’s margin optimization initiatives” and highlighted strong operational delivery, particularly in the clinical pharmacology unit, which reported high demand and successful project execution. Interim CEO Neupert also noted that backlog and book-to-bill metrics remained healthy, though new business wins from smaller biotech customers were impacted by customer hesitancy during the CEO transition.

Is now the time to buy FTRE? Find out in our full research report (it’s free).

While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.

Our Top 5 Analyst Questions From Fortrea’s Q2 Earnings Call

• Eric White Coldwell (Baird) asked whether smaller biotech clients delayed or redirected projects due to leadership changes; CFO Jill McConnell confirmed most chose other providers but expects a rebound as leadership stabilizes. CEO Anshul Thakral outlined his approach to commercial operations, emphasizing customer engagement and delivery quality.
• Justin D. Bowers (Deutsche Bank) requested an update on demand trends and Phase I business capacity constraints. Thakral described the demand pipeline as improving, with clinical pharmacology capacity still stretched, requiring ongoing third-party support. McConnell added that efforts are underway to bring more work in-house.
• Patrick Bernard Donnelly (Citi) asked about cancellations and margin outlook. McConnell reported cancellations remained historically low and detailed that margin improvements would come from annualizing current cost initiatives, especially in SG&A, with pricing discipline maintained despite competitive pressure.
• Tucker Remmers (Jefferies) questioned the expected revenue step down in the second half; McConnell explained this was due to the completion of a large, pass-through heavy study and indicated future quarters would have better margins as cost savings materialize.
• Elizabeth Hammell Anderson (Evercore ISI) sought clarification on the revenue guidance increase and its impact on EBITDA. McConnell clarified the guidance lift was driven by operational factors, not foreign exchange, and explained that EBITDA guidance was held steady out of prudence despite margin progress.

Catalysts in Upcoming Quarters

In the coming quarters, our analysts will focus on (1) whether Fortrea can regain momentum in winning new biotech business as leadership settles, (2) the realization of additional SG&A savings and their impact on margins, and (3) further adoption and operational impact of the Accelerate digital platform modules, especially Risk Radar. Monitoring improvements in cash flow and backlog conversion will also be critical for assessing execution.

Fortrea currently trades at $7.31, up from $6.58 just before the earnings. In the wake of this quarter, is it a buy or sell? The answer lies in our full research report (it’s free).

Our Favorite Stocks Right Now

When Trump unveiled his aggressive tariff plan in April 2025, markets tanked as investors feared a full-blown trade war. But those who panicked and sold missed the subsequent rebound that’s already erased most losses.

Don’t let fear keep you from great opportunities and take a look at Top 5 Strong Momentum Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today.

StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.